Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

You may also find page 9 to be of interest. It may explain why the company initially stated there would be an interim report, but has since abstained:

FDA strongly discourages disseminating data from ongoing trials. Knowledge of accumulating data by trial investigators and patients can adversely affect patient accrual, adherence, and retention, as well as endpoint assessment, compromising the ability of the trial to reliably achieve its objective in a timely manner.

Clear as day.

In the wake of the C*D* disaster, following the current-most FDA guidance to the letter seems prudent.

Bingo. They had good results. Leronlimab could save lives and reduce costs/suffering associated with COVID. CYDY's management acted a fool though. Anyone clamoring for anymore pre-topline results from IPIX did not pay attention to what happened here.

Don't mess with the FDA when the state things clearly. Follow the protocol and pray for EUA-worthy results.

Go IPIX!